Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Neumirna Therapeutics ApS
APS
Active
Advertising protection
CVR 41696451
A.C. Meyers Vænge 15, 2450
København SV
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2020 · 5 years old
11 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Neumirna Therapeutics ApS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
0M
-1M
-3M
-4M
-6M
-6M
2021
-5M
2022
-5M
2023
-5M
2024
EBITDA
DKK millions
0M
-3M
-5M
-8M
-10M
-7M
2021
-6M
+14%
2022
-8M
-33%
2023
-8M
0%
2024
Income statement
DKK thousands
Item
2021
2022
2023
2024
Gross profit
-5.781
-4.661
-5.476
-5.496
Staff expenses
-1.420
-1.701
-2.154
-2.794
EBITDA
-7.201
-6.361
-7.630
-8.290
Depreciation & amort.
-0
-0
-0
-0
EBIT
-7.201
-6.361
-7.630
-8.290
Net financials
-414
-419
-2.114
-428
Profit before tax
-7.615
-6.780
-9.745
-8.719
Tax
-1.547
-1.488
-1.710
-1.765
Net profit
-6.068
-5.292
-8.034
-6.954
Balance sheet
DKK thousands
Item
2021
2022
2023
2024
Total assets
5.746
8.972
6.255
5.507
Equity
1.859
-3.434
-11.468
-18.422
Long-term debt
3.318
11.081
16.840
156
Short-term debt
569
1.324
883
23.773
Total debt
3.887
12.406
17.723
23.929
Financial ratios
5-year trend
EBITDA margin (of gross profit)
-829035200.0%
This company
2021
2024
Equity ratio
-334.5%
This company
38.2%
Market median
-976% vs market
2021
2024
Return on equity
-695420100.0%
This company
18.4%
Market median
-3779457165% vs market
2021
2024
Net profit margin (of gross profit)
-695420100.0%
This company
2021
2024
Asset turnover (of gross profit)
-1.00×
This company
2021
2024
Debt / equity
1.30×
This company
0.62×
Market median
-110% vs market
2021
2024
Annual reports & filings
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via CVR / Virk · Period 2020-09-21 – 2021-12-31
View
PDF
More on Neumirna Therapeutics ApS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
